Senores Pharmaceuticals Limited, announced its unaudited financial results for the quarter ended June 30, 2026, reporting strong financial and operational performance across key business segments.
Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its unaudited financial results for the quarter ended June 30, 2026, reporting strong financial and operational performance across key business segments.
The company delivered broad-based growth during Q1 FY27, supported by continued momentum in Regulated and Emerging Markets, improved profitability, expansion of its product portfolio, and increasing manufacturing and commercialization capabilities.
Strong Financial Performance
During Q1 FY27, Senores reported total revenue of ₹180.2 crore, registering a 35.9% year-on-year growth. EBITDA increased sharply to ₹54 crore, growing 87% YoY, while profit after tax (PAT) reached ₹31 crore, reflecting a 56% YoY increase. The strong improvement in EBITDA was accompanied by an approximately 800 basis points expansion in margins on a year-on-year basis, reflecting the company’s continued focus on manufacturing and cost efficiency.
Performance Across Key Business Segments
Regulated Markets
The Regulated Markets business continued to be a key growth driver for Senores.
Revenue from Regulated Markets stood at ₹127.8 crore in Q1 FY27, registering a strong 41.9% year-on-year growth. The performance was supported by continuous expansion of the company’s product portfolio and differentiated sales and distribution channels.
Senores has nearly doubled its Regulated Markets portfolio over the past year, increasing its approved ANDAs from 30 as of June 2025 to 58 approved ANDAs as of June 2026. Of these, 23 ANDAs have already been commercialized, strengthening the company’s product pipeline and providing visibility for future launches.
Emerging Markets
The Emerging Markets business continued on a steady growth trajectory.
Revenue from Emerging Markets stood at ₹37.6 crore in Q1 FY27, reflecting a 29.6% year-on-year growth. EBITDA margins stood at approximately 14%, supported by an increasing focus on niche products and streamlined go-to-market strategies. The business has also turned cash flow positive, reflecting continued improvement in operational efficiency and financial performance.
Branded Generics
The India-focused Branded Generics business recorded revenue of ₹8 crore in Q1 FY27, compared with ₹8.2 crore in the corresponding quarter of the previous year.
Strategic Business Developments
Senores continued to strengthen its manufacturing and commercialization platform during the quarter, supporting its long-term growth strategy across regulated and emerging markets.
The addition of the Baroda-based USFDA-approved manufacturing plant is expected to enhance scalability, deepen access to Regulated Markets, enable accelerated product launches, improve operating leverage and margins, and expand CDMO and CMO opportunities.
Production has already ramped up at the Apnar facility, with full-scale expansion expected over the next 12–18 months. The facility is expected to further strengthen Senores’ manufacturing capabilities and support the company’s growth across its global markets.
The company’s specific-purpose marketing and distribution subsidiaries are also expected to scale up significantly over the coming years, supporting the structural expansion of its U.S. business.
Commenting on the Q1 FY27 performance, Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited, said: “We have delivered a healthy performance in the first quarter of FY27, building on the strong momentum from the previous year and driven by our well-defined strategic priorities, despite a challenging operating environment.
Our Regulated Markets business delivered strong performance in Q1 FY27, registering 42% year-over-year revenue growth. This was driven by the continuous expansion of our product portfolio and differentiated sales and distribution channels. Through a balanced blend of in-house development and targeted acquisitions, we have strategically strengthened our ANDA portfolio.
The Emerging Markets business is also progressing steadily. With our continued shift towards niche products, we are now at near mid-teens EBITDA margins, while importantly, the business has turned cash flow positive.
The addition of the Baroda-based USFDA-approved manufacturing plant enhances our scalability, deepens our access to Regulated Markets, enables accelerated product launches, improves operating leverage and margins, and expands our CDMO and CMO opportunities. Production is already ramped up at the Apnar facility, with full scale-up and further expansion expected over the next 12–18 months.
Our specific-purpose marketing and distribution subsidiaries are expected to scale up significantly over the next few years and will structurally advance our entire U.S. business to multifold.
Overall, we have continued to deliver on our stated commitments through disciplined execution, operational excellence, and a relentless focus on growth. Our ability to consistently execute across functions while maintaining financial discipline reflects the resilience of our business model, the credibility of our long-term strategy, and the execution-driven culture deeply embedded across Senores.
We remain confident in sustaining this momentum in the years ahead, led by a robust product pipeline, expanded manufacturing capacities, and a strengthened R&D infrastructure.”
Outlook
Senores remains focused on sustaining its growth momentum through a differentiated product portfolio, continued expansion of its Regulated Markets business, strengthening of its Emerging Markets platform, and scaling of its manufacturing and commercialization capabilities.
With a strong product pipeline, increased visibility of commercial launches over the coming quarters, expanded manufacturing capacity, and a strengthened R&D infrastructure, the company remains well positioned to deliver strong revenue growth and expanding profitability in FY27 and beyond.
